Author Correction: Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients

Yongliang Zhang,Yu Yao,Yaping Xu,Lifeng Li,Yan Gong,Kai Zhang,Meng Zhang,Yanfang Guan,Lianpeng Chang,Xuefeng Xia,Lin Li,Shuqin Jia,Qiang Zeng

DOI: https://doi.org/10.1038/s41467-021-21285-2

IF: 16.6

2021-02-10

Nature Communications

Abstract:A Correction to this paper has been published: https://doi.org/10.1038/s41467-021-21285-2

multidisciplinary sciences

What problem does this paper attempt to address?

Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients (vol 12, 11, 2021)

Yongliang Zhang,Yu Yao,Yaping Xu,Lifeng Li,Yan Gong,Kai Zhang,Meng Zhang,Yanfang Guan,Lianpeng Chang,Xuefeng Xia,Lin Li,Shuqin Jia,Qiang Zeng

DOI: https://doi.org/10.1038/s41467-021-21285-2

IF: 16.6

2021-01-01

Nature Communications

Abstract:A Correction to this paper has been published: https://doi.org/10.1038/s41467-021-21285-2
Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients (vol 11, 655709, 2021)

Jun Li,Sile Han,Cuiyun Zhang,Yanlin Luo,Li Wang,Ping Wang,Yi Wang,Qingxin Xia,Xiaoyan Wang,Bing Wei,Jie Ma,Hongle Li,Yongjun Guo

DOI: https://doi.org/10.3389/fonc.2021.840551

IF: 4.7

2022-01-01

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.655709.].
Author Correction: Multiple omics integrative analysis identifies GARS1 as a novel prognostic and immunological biomarker: from pan-cancer to bladder cancer

Weihui Liu,Chengcheng Wei,Qingliu He,Zhaohui Chen,Wei Zhuang,Yihong Guo,Xueyi Xue

DOI: https://doi.org/10.1038/s41598-024-76904-x

IF: 4.6

2024-10-26

Scientific Reports

Abstract:Scientific Reports - Author Correction: Multiple omics integrative analysis identifies GARS1 as a novel prognostic and immunological biomarker: from pan-cancer to bladder cancer

multidisciplinary sciences
Analysis of genomic alterations in pan-cancer from a large real-world Chinese population.

Zhouhuan Dong,Jie Gao,Fengwei Zhu,Fei Gai,Wenqing Su,Zhixin Liang,Xiaodong Tian,Huaiyin Shi

DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.10568

IF: 45.3

2022-06-01

Journal of Clinical Oncology

Abstract:10568 Background: Effective targeted therapy sorely depends on comprehensive and precise genomic profiling. Besides, single nucleotide variations (SNVs) and InDels, gene fusions, as drivers and therapeutic targets of great importance, are not yet well characterized in Chinese patients. Methods: Formalin-fixed, paraffin-embedded (FFPE) tumor tissues from 1,384 pan-cancer patients were collected and sequenced using next-generation sequencing (NGS) targeting 40 cancer genes including SNV, fusion and assessing copy number variation (CNV) (AmoyDx HANDLE Classic Panel). qPCR and fluorescence in situ hybridization (FISH) were further applied to verify NGS detected fusion genes. Results: 1,384 patients were recruited including 890 lung cancers, 272 colorectal cancers, 174 gastric cancers, and 48 endometrial cancers. The prevalence of fusion genes (5.49%), including ALK-fusion (2.67%), ROS1-fusion (0.94%), RET-fusion (0.72%), NRG1-fusion (0.29%), and NTRK-fusion (0.07%), was nearly double the frequency of previously reported data from East Asians. Prevalence of fusion genes varied in different types of cancers. For instance, ALK (3.7%), ROS1 (1.5%), RET (1.0%) and NRG1 (0.2%) fusions were largely found in patients with non-small cell lung cancer (NSCLC), and were rarely detected in other cancer types. Further analysis of genomic alterations in fusion-positive patients revealed that, TP53 (21%) was the most frequently co-occurred mutated gene with ALK fusion, while RET fusions and ROS1 fusions were rarely accompanied by other mutated genes. In addition, two patients with RBPMS- NRG1 fusion were accompanied by BRAF and RB1 mutations, whereas no co-occurred mutation was found in patients with other partners of NRG1. Patients with inconsistent results of RNA-based NGS and FISH validation fusions are still being followed for treatment and survival, updated data will be available at the time of the presentation. Conclusions: Genomic alterations in real-world Chinese populations have specific characteristics, especially fusion genes. Further characterization of these variants is essential for clinics to guide appropriate targeted therapies.

oncology
The Early Diagnosis in Lung Cancer by the Detection of Circulating Tumor DNA

Geng Tian,Xiaohua Li,Yuancai Xie,Feiyue Xu,Dan Yu,Fengjun Cao,Xuanbin Wang,Fenglei Yu,Weiquan Zhong,Shixin Lu,Xiaonian Tu,Xumei Yao,Jiankui He,Chaoyu Liu

DOI: https://doi.org/10.1101/189340

2017-09-15

Abstract:Background Remarkable advances for clinical diagnosis and treatment in cancers including lung cancer involve cell-free circulating tumor DNA (ctDNA) detection through next generation sequencing. However, before the sensitivity and specificity of ctDNA detection can be widely recognized, the consistency of mutations in tumor tissue and ctDNA should be evaluated. The urgency of this consistency is extremely obvious in lung cancer to which great attention has been paid to in liquid biopsy field. Methods We have developed an approach named systematic error correction sequencing (Sec-Seq) to improve the evaluation of sequence alterations in circulating cell-free DNA. Averagely 10 ml preoperative blood samples were collected from 30 patients containing pulmonary space occupying pathological changes by traditional clinic diagnosis. cfDNA from plasma, genomic DNA from white blood cells, and genomic DNA from solid tumor of above patients were extracted and constructed as libraries for each sample before subjected to sequencing by a panel contains 50 cancer-associated genes encompassing 29 kb by custom probe hybridization capture with average depth >40000, 7000, or 6300 folds respectively. Results Detection limit for mutant allele frequency in our study was 0.1%. The sequencing results were analyzed by bioinformatic expertise based on our previous studies on the baseline mutation profiling of circulating cell-free DNA and the clinicopathological data of these patients. Among all the lung cancer patients, 78% patients were predicted as positive by ctDNA sequencing when the shreshold was defined as at least one of the hotspot mutations detected in the blood (ctDNA) was also detected in tumor tissue. Pneumonia and pulmonary tuberculosis were detected as negative according to the above standard. When evaluating all hotspots in driver genes in the panel, 24% mutations detected in tumor tissue (tDNA) were also detected in patients blood (ctDNA). When evaluating all genetic variations in the panel, including all the driver genes and passenger genes, 28% detected in tumor tissue (tDNA) were also detected in patients blood (ctDNA). Positive detection rates of plasma ctDNA in stage I lung cancer patients is 85%, compared with 17% of tumor biomarkers. Conclusion We demonstrated the importance of sequencing both circulating cell-free DNA and genomic DNA in tumor tissue for ctDNA detection in lung cancer currently. We also determined and confirmed the consistency of ctDNA and tumor tissue through NGS according to the criteria explored in our studies. Our strategy can initially distinguish the lung cancer from benign lesions of lung. Our work shows that the consistency will be benefited from the optimization in sensitivity and specificity in ctDNA detection.
Comprehensive Analysis of Genomic Alterations Detected by Next-Generation Sequencing-Based Tissue and Circulating Tumor DNA Assays in Chinese Patients with Non-Small Cell Lung Cancer

Hua Yang,Junjie Zhang,Lemeng Zhang,Xiaoping Wen,Yongzhong Luo,Dingquan Yao,Tianli Cheng,Huanqing Cheng,Huina Wang,Feng Lou,Jing Guo,Xiayuan Liang,Shanbo Cao,Jianhua Chen

DOI: https://doi.org/10.3892/ol.2019.10791

IF: 45.3

2019-01-01

Journal of Clinical Oncology

Abstract:While tumor genotyping is the standard treatment for patients with non-small cell lung cancer (NSCLC), spatial and temporal tumor heterogeneity and insufficient specimens can lead to limitations in the use of tissue-based sequencing. Circulating tumor DNA (ctDNA) fully encompasses tumor-specific sequence alterations and offers an alternative to tissue sample biopsies. However, few studies have evaluated whether the frequency of multiple genomic alterations observed following ctDNA sequencing is similar to that observed following tissue sequencing in NSCLC. Therefore, in the present study, targeted next-generation sequencing (NGS) was performed on tissue and plasma ctDNA samples in 99 patients with NSCLC. Overall, the frequencies of genetic alterations detected in ctDNA were positively correlated with those detected via tissue profiling (r=0.812; P=0.022). Genomic data revealed significant mutual exclusivity between alterations in epidermal growth factor receptor (EGFR) and tumor protein 53 (TP53; P=0.020), and between alterations in EGFR and KRAS (P=0.008), as well as potential mutual exclusivity between alterations in EGFR and Erb-B2 receptor tyrosine kinase 2 (P=0.059). Furthermore, the EGFR mutant allele frequency (MAF) was positively correlated with the TP53 MAF in individual tumors (r=0.773; P=0.005), and there was a marked difference in the EGFR MAF between patients with and without the TP53 mutation (P=0.001). Levels of the tumor serum marker CA242 in patients with ctDNA-detectable mutations were higher compared with those in patients without ctDNA-detectable mutations. The data from the present study highlight the importance of tissue and plasma ctDNA screening by NGS to guide personalized therapy and promote the clinical management of patients with NSCLC.
Publisher Correction: Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing

Xinyi Guo,Yuanyuan Zhang,Liangtao Zheng,Chunhong Zheng,Jintao Song,Qiming Zhang,Boxi Kang,Zhouzerui Liu,Liang Jin,Rui Xing,Ranran Gao,Lei Zhang,Minghui Dong,Xueda Hu,Xianwen Ren,Dennis Kirchhoff,Helge Gottfried Roider,Tiansheng Yan,Zemin Zhang

DOI: https://doi.org/10.1038/s41591-018-0167-7

Abstract:In the version of this article originally published, the P statistic described in Fig. 3d was incorrect. It was described as "P < 22 × 10-16". It should have been "P < 2.2 × 10-16". Also, the "CD8+ Treg" label in Fig. 4f was incorrect. It should have been "CD4+ Treg". The errors have been corrected in the HTML and PDF versions of this article.
Supplementary Data from Genomic Landscape and Tumor Mutational Burden Determination of Circulating Tumor DNA in over 5,000 Chinese Patients with Lung Cancer

Jie Shi,Zhiyu Wang,Junping Zhang,Yaping Xu,Xiao,Xiangming Quan,Ying Bai,Xia Yang,Zongjuan Ming,Xiaojin Guo,Huijing Feng,Xiaoling Yang,Xiaofei Zhuang,Fei Han,Kai Wang,Yonglei Shi,Yu Lei,Jun Bai,Shuanying Yang

DOI: https://doi.org/10.1158/1078-0432.ccr-21-1537

IF: 13.801

2021-01-01

Clinical Cancer Research

Abstract:Abstract Purpose: Having emerged as a noninvasive and clinically applicable approach for molecular determination of lung cancer, a genomic overview of circulating tumor DNA (ctDNA) of large-scale cohort may be helpful in novel biomarker development and therapeutic innovation. Experimental Design: Primary cohort encompasses 5,671 blood samples from 4,892 patients with lung cancer. Pair-wise tissue samples from 579 patients and additional 358 sample pairs were collected to evaluate the correlation between blood and tissue tumor mutational burden (TMB). Parallel sequencing with plasma/tissue and white blood cells was performed using a 1,021-gene panel. Results: Histologic subtyping was the most relevant to ctDNA detectability independent of other demographic characteristics, with small cell lung cancer showing the highest detectability, ctDNA abundance, and blood TMB (bTMB). Mutational landscape demonstrated significant differences, and integrated clonality analysis highlighted distinct driver-pattern and functional pathway interaction among various subtypes. The clonality and concurrent genes of EGFR mutations could predict the therapeutic efficacy of tyrosine kinase inhibitors (TKI), and RB1 mutations in non–small cell lung cancer characterized a subset with high bTMB, elevated ctDNA level, and potential small cell transformation. Most importantly, we developed an adjusted algorithm for bTMB in samples with extremely low ctDNA level and validated its correlation with tissue TMB in an independent cohort. Conclusions: ctDNA could serve as a promising alternative in genomic profiling for lung cancer. The novel identification of ctDNA clonality and adjusted bTMB might improve therapeutic and prognostic evaluation. This dataset was also a valuable resource for the development of new therapeutic targets and new genomically guided clinical trials.
Author Correction: Drug screening of cancer cell lines and human primary tumors using droplet microfluidics

Ada Hang-Heng Wong,Haoran Li,Yanwei Jia,Pui-In Mak,Rui Paulo da Silva Martins,Yan Liu,Chi Man Vong,Hang Cheong Wong,Pak Kin Wong,Haitao Wang,Heng Sun,Chu-Xia Deng

DOI: https://doi.org/10.1038/s41598-019-55120-y

IF: 4.6

2019-01-01

Scientific Reports

Abstract:n amendment to this paper has been published and can be accessed via a link at the top of the paper.
Author Correction to “Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy” [acta Pharm Sin B 12 (2022) 4224–4234]

Zekun Li,Yongchun Pan,Shizheng Du,Yayao Li,Chao Chen,Hongxiu Song,Yueyao Wu,Xiaowei Luan,Qiang Xu,Xiaoxiang Guan,Yujun Song,Xin Han

DOI: https://doi.org/10.1016/j.apsb.2023.09.002

IF: 14.903

2024-01-01

Acta Pharmaceutica Sinica B

Abstract:[This corrects the article DOI: 10.1016/j.apsb.2022.06.016.].
Corrigendum: A comprehensive analysis of HAVCR1 as a prognostic and diagnostic marker for pan-cancer

Sheng Liu,Wenting Tang,Jing Cao,Mei Shang,Sun Hengchang,Jiao Gong,Bo Hu

DOI: https://doi.org/10.3389/fgene.2024.1357409

IF: 3.7

2024-01-26

Frontiers in Genetics

Abstract:[This corrects the article DOI: 10.3389/fgene.2022.904114.].

genetics & heredity
Corrigendum: Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients

Jun Li,Sile Han,Cuiyun Zhang,Yanlin Luo,Li Wang,Ping Wang,Yi Wang,Qingxin Xia,Xiaoyan Wang,Bing Wei,Jie Ma,Hongle Li,Yongjun Guo

DOI: https://doi.org/10.3389/fonc.2021.840551

IF: 4.7

2022-01-14

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.655709.].

oncology
Author Correction: Genetic polymorphisms of lncRNA-p53 regulatory network genes are associated with concurrent chemoradiotherapy toxicities and efficacy in nasopharyngeal carcinoma patients

Youhong Wang,Zhen Guo,Yu Zhao,Yi Jin,Liang An,Bin Wu,Zhaoqian Liu,Xiaoping Chen,Xiang Chen,Honghao Zhou,Hui Wang,Wei Zhang

DOI: https://doi.org/10.1038/s41598-017-16511-1

IF: 4.6

2017-01-01

Scientific Reports

Abstract:correction to this article has been published and is linked from the HTML version of this paper. The error has been fixed in the paper.
Corrigendum: Molecular Portrait of GIST Associated With Clinicopathological Features: A Retrospective Study With Molecular Analysis by a Custom 9-Gene Targeted Next-Generation Sequencing Panel

Haoran Qian,Na Yan,Xiaotong Hu,Junchang Jiang,Zhengzheng Cao,Dan Shen

DOI: https://doi.org/10.3389/fgene.2022.945357

IF: 3.7

2022-06-28

Frontiers in Genetics

Abstract:[This corrects the article DOI: 10.3389/fgene.2022.864499.].

genetics & heredity
Genomic Landscape and Tumor Mutational Burden Determination of Circulating Tumor DNA in Over 5,000 Chinese Patients with Lung Cancer

Jie Shi,Zhiyu Wang,Junping Zhang,Yaping Xu,Xiao Xiao,Xiangming Quan,Ying Bai,Xia Yang,Zongjuan Ming,Xiaojin Guo,Huijing Feng,Xiaoling Yang,Xiaofei Zhuang,Fei Han,Kai Wang,Yonglei Shi,Yu Lei,Jun Bai,Shuanying Yang

DOI: https://doi.org/10.1158/1078-0432.ccr-21-1537

IF: 13.801

2021-08-26

Clinical Cancer Research

Abstract:Abstract Purpose: Having emerged as a noninvasive and clinically applicable approach for molecular determination of lung cancer, a genomic overview of circulating tumor DNA (ctDNA) of large-scale cohort may be helpful in novel biomarker development and therapeutic innovation. Experimental Design: Primary cohort encompasses 5,671 blood samples from 4,892 patients with lung cancer. Pair-wise tissue samples from 579 patients and additional 358 sample pairs were collected to evaluate the correlation between blood and tissue tumor mutational burden (TMB). Parallel sequencing with plasma/tissue and white blood cells was performed using a 1,021-gene panel. Results: Histologic subtyping was the most relevant to ctDNA detectability independent of other demographic characteristics, with small cell lung cancer showing the highest detectability, ctDNA abundance, and blood TMB (bTMB). Mutational landscape demonstrated significant differences, and integrated clonality analysis highlighted distinct driver-pattern and functional pathway interaction among various subtypes. The clonality and concurrent genes of EGFR mutations could predict the therapeutic efficacy of tyrosine kinase inhibitors (TKI), and RB1 mutations in non–small cell lung cancer characterized a subset with high bTMB, elevated ctDNA level, and potential small cell transformation. Most importantly, we developed an adjusted algorithm for bTMB in samples with extremely low ctDNA level and validated its correlation with tissue TMB in an independent cohort. Conclusions: ctDNA could serve as a promising alternative in genomic profiling for lung cancer. The novel identification of ctDNA clonality and adjusted bTMB might improve therapeutic and prognostic evaluation. This dataset was also a valuable resource for the development of new therapeutic targets and new genomically guided clinical trials.

oncology
Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

Xing Yi Woo,Jessica Giordano,Anuj Srivastava,Zi-Ming Zhao,Michael W. Lloyd,Roebi de Bruijn,Yun-Suhk Suh,Rajesh Patidar,Li Chen,Sandra Scherer,Matthew H. Bailey,Chieh-Hsiang Yang,Emilio Cortes-Sanchez,Yuanxin Xi,Jing Wang,Jayamanna Wickramasinghe,Andrew V. Kossenkov,Vito W. Rebecca,Hua Sun,R. Jay Mashl,Sherri R. Davies,Ryan Jeon,Christian Frech,Jelena Randjelovic,Jacqueline Rosains,Francesco Galimi,Andrea Bertotti,Adam Lafferty,Alice C. O’Farrell,Elodie Modave,Diether Lambrechts,Petra ter Brugge,Violeta Serra,Elisabetta Marangoni,Rania El Botty,Hyunsoo Kim,Jong-Il Kim,Han-Kwang Yang,Charles Lee,Dennis A. Dean,Brandi Davis-Dusenbery,Yvonne A. Evrard,James H. Doroshow,Alana L. Welm,Bryan E. Welm,Michael T. Lewis,Bingliang Fang,Jack A. Roth,Funda Meric-Bernstam,Meenhard Herlyn,Michael A. Davies,Li Ding,Shunqiang Li,Ramaswamy Govindan,Claudio Isella,Jeffrey A. Moscow,Livio Trusolino,Annette T. Byrne,Jos Jonkers,Carol J. Bult,Enzo Medico,Jeffrey H. Chuang,,

DOI: https://doi.org/10.1038/s41588-021-00811-4

IF: 30.8

2021-02-19

Nature Genetics

Abstract:A Correction to this paper has been published: https://doi.org/10.1038/s41588-021-00811-4.

genetics & heredity
Erratum: Author Correction to "Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy" [acta Pharm Sin B (2022) 4224-4234].

Zekun Li,Yongchun Pan,Shiyu Du,Yayao Li,Chao Chen,Hongxiu Song,Yueyao Wu,Xiaowei Luan,Qin Xu,Xiaoxiang Guan,Yujun Song,Xin Han

DOI: https://doi.org/10.1016/j.apsb.2023.09.002

IF: 14.903

2023-01-01

Acta Pharmaceutica Sinica B

Abstract:[This corrects the article DOI: 10.1016/j.apsb.2022.06.016.].
Landscape of somatic alterations in large-scale solid tumors from an Asian population

Liqun Wu,Herui Yao,Hui Chen,Aodi Wang,Kun Guo,Wenli Gou,Yanfei Yu,Xiang Li,Ming Yao,Shaohua Yuan,Fei Pang,Jinwei Hu,Lijuan Chen,Wenjin Liu,Jicheng Yao,Shuirong Zhang,Xiaowei Dong,Weifeng Wang,Jing Hu,Qi Ling,Songming Ding,Yan Wei,Qiang Li,Weichun Cao,Shuang Wang,Yang Di,Feiling Feng,Gang Zhao,Jian Zhang,Ling Huang,Jia Xu,Wangjun Yan,Zhongsheng Tong,Da Jiang,Tao Ji,Qiao Li,Ling Xu,Huiying He,Liang Shang,Jin Liu,Kefeng Wang,Duoguang Wu,Jingnan Shen,Ye Liu,Ting Zhang,Chaojie Liang,Yusheng Wang,Yanhong Shang,Jianji Guo,Guanbiao Liang,Shifeng Xu,Junfeng Liu,Kai Wang,Minghui Wang

DOI: https://doi.org/10.1038/s41467-022-31780-9

IF: 16.6

2022-07-24

Nature Communications

Abstract:Extending the benefits of tumor molecular profiling for all cancer patients requires a comprehensive analysis of tumor genomes across distinct patient populations worldwide. In this study, we perform deep next-generation DNA sequencing (NGS) from tumor tissues and matched blood specimens from over 10,000 patients in China by using a 450-gene comprehensive assay, developed and implemented under international clinical regulations. We perform a comprehensive comparison of somatically altered genes, the distribution of tumor mutational burden (TMB), gene fusion patterns, and the spectrum of various somatic alterations between Chinese and American patient populations. Here, we show 64% of cancers from Chinese patients in this study have clinically actionable genomic alterations, which may affect clinical decisions related to targeted therapy or immunotherapy. These findings describe the similarities and differences between tumors from Chinese and American patients, providing valuable information for personalized medicine.

multidisciplinary sciences
Corrigendum: Sequential PET/CT and pathological biomarker crosstalk predict response to PD-1 blockers alone or combined with sunitinib in propensity score-matched cohorts of cancer of unknown primary treatment

Youlong Wang,Qi Huang,Guanqing Zhong,Jun Lv,Qinzhi Guo,Yifei Ma,Xinjia Wang,Jiling Zeng

DOI: https://doi.org/10.3389/fonc.2024.1376408

IF: 4.7

2024-02-29

Frontiers in Oncology

Abstract:This article is a correction to: Sequential PET/CT and pathological biomarker crosstalk predict response to PD-1 blockers alone or combined with sunitinib in propensity score-matched cohorts of cancer of unknown primary treatment

oncology
Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer

Xiaofei Zhang,Tiebo Mao,Bei Zhang,Haiyan Xu,Jiujie Cui,Feng Jiao,Dongqin Chen,Yu Wang,Jiong Hu,Qing Xia,Weiyu Ge,Shumin Li,Ming Yue,Jingyu Ma,Jiayu Yao,Yongchao Wang,Yanling Wang,Daiyuan Shentu,Xiao Zhang,Shiqing Chen,Yuezong Bai,Yuexiang Wang,Xuebin Zhang,Qiang Liu,Yongwei Sun,Deliang Fu,Yingbin Liu,Lei Xiong,Liwei Wang

DOI: https://doi.org/10.1016/j.ebiom.2022.103897

IF: 11.205

2022-03-01

EBioMedicine

Abstract:BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a malignant tumor with an extremely poor prognosis. Effective targets for anticancer therapy confirmed in PDAC are limited. However, the characteristics of genomics have not been fully elucidated in large-scale patients with PDAC from China.METHODS: We collected both blood and tissue samples from 1080 Chinese patients with pancreatic cancer and retrospectively investigated the genomic landscape using next-generation sequencing (NGS).FINDINGS: We found recurrent somatic mutations in KRAS (83.2%), TP53 (70.6%), CDKN2A (28.8%), SMAD4 (23.0%), ARID1A (12.8%) and CDKN2B (8.9%) in Chinese PDAC patients. Compared with primary pancreatic cancers, more genomic alterations accumulated especially cell cycle regulatory gene variants (45.4% vs 31.6%, P < 0.001) were observed in metastatic tumors. The most common mutation site of KRAS is p.G12D (43.6%) in pancreatic cancer. Patients with KRAS mutations were significantly associated with older age and mutations in the other three driver genes, while KRAS wild-type patients contained more fusion mutations and alternative mechanisms of RTK/Ras/MAPK pathway including a number of clinically targetable mutations. KRAS mutations in Chinese cohort were significantly lower than those in Western cohorts (all P < 0.05). A total of 252 (23.3%) patients with the core DNA damage response (DDR) gene mutations were detected. ATM (n =59, 5.5%) was the most frequent mutant DDR gene in patients with pancreatic cancer from China. Patients with germline DDR gene mutations were younger (P = 0.018), while patients with somatic DDR gene mutations were more likely to accumulate in metastatic lesions (P < 0.001) and had higher TMB levels (P < 0.001). In addition, patients with mutant DDR genes and patients carrying TP53 mutation were observed mutually exclusive (P < 0.001).INTERPRETATION: We demonstrated the real-world genomic characteristics of large-scale patients with pancreatic cancer from China which may have promising implications for further clinical significance and drug development.FUNDING: The funders are listed in the Acknowledgement.

medicine, research & experimental

Author Correction: Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients

Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients (vol 12, 11, 2021)

Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients (vol <i>11</i>, <i>655709</i>, <i>2021</i>)

Author Correction: Multiple omics integrative analysis identifies GARS1 as a novel prognostic and immunological biomarker: from pan-cancer to bladder cancer

Analysis of genomic alterations in pan-cancer from a large real-world Chinese population.

The Early Diagnosis in Lung Cancer by the Detection of Circulating Tumor DNA

Comprehensive Analysis of Genomic Alterations Detected by Next-Generation Sequencing-Based Tissue and Circulating Tumor DNA Assays in Chinese Patients with Non-Small Cell Lung Cancer

Publisher Correction: Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing

Supplementary Data from Genomic Landscape and Tumor Mutational Burden Determination of Circulating Tumor DNA in over 5,000 Chinese Patients with Lung Cancer

Author Correction: Drug screening of cancer cell lines and human primary tumors using droplet microfluidics

Author Correction to “Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy” [acta Pharm Sin B 12 (2022) 4224–4234]

Corrigendum: A comprehensive analysis of HAVCR1 as a prognostic and diagnostic marker for pan-cancer

Corrigendum: Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients

Author Correction: Genetic polymorphisms of lncRNA-p53 regulatory network genes are associated with concurrent chemoradiotherapy toxicities and efficacy in nasopharyngeal carcinoma patients

Corrigendum: Molecular Portrait of GIST Associated With Clinicopathological Features: A Retrospective Study With Molecular Analysis by a Custom 9-Gene Targeted Next-Generation Sequencing Panel

Genomic Landscape and Tumor Mutational Burden Determination of Circulating Tumor DNA in Over 5,000 Chinese Patients with Lung Cancer

Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

Erratum: Author Correction to "Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy" [acta Pharm Sin B (2022) 4224-4234].

Landscape of somatic alterations in large-scale solid tumors from an Asian population

Corrigendum: Sequential PET/CT and pathological biomarker crosstalk predict response to PD-1 blockers alone or combined with sunitinib in propensity score-matched cohorts of cancer of unknown primary treatment

Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer